BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Churn-Shiouh Gau

​​

Session 12 – Recent Development of Game-Changing Tumor Agnostic Therapeutics

Date:23 July (Friday)
Time:  12:20 – 13:50 (GMT+8)

Churn-Shiouh Gau

Associate Professor
National Taiwan University

Dr. Gau is now the adjunct professor and the director of the Platform for Research and Inspiration in Regulatory Science, School of Pharmacy, National Taiwan University, and the distinguished senior specialist at the Ching-Kang Foundation for pharmacy Promotion. Dr. Gau also serves as the project director for the Office of Sustainable Platform for Big Data in Health, a program sponsored by the Ministry of Health and Welfare, Taiwan in 2021.

Dr. Gau had been the Chief Executive Director of Center for Drug Evaluation (CDE), Taiwan for 9 years, from April 1, 2011 to Feb. 29, 2020. CDE was established by Department of Health (DOH, now MOHW) in 1998, to assist the technical evaluation for market approval of drugs and medical devices. Dr. Gau was appointed as the Deputy Executive Director of CDE from June 2006 to Aug. 2009.
 
Dr. Gau received her Ph.D. degree in Pharmaceutics from the School of Pharmacy, University of Wisconsin-Madison, USA, in 1992. After that she returned to the School of Pharmacy, National Taiwan University (NTU) as a faculty member. During Aug. 1996 to July 2000, she was appointed as the Director of the Department of Pharmacy, NTU Hospital, one of the largest university-affiliated medical centers in Taiwan.

Prior to joining CDE, Dr. Gau served as expert/advisor in many Committees for MOHW, specializing in the evaluation of new drug application, assessment of drug safety, and accreditation of teaching hospital. Dr. Gau had led the projects for establishing the National ADR Reporting System in Taiwan for many years. Dr. Gau’s researches focus on the use of claim database of the National Health Insurance program of Taiwan to study the prescription pattern of drug utilization, the adherence of drug usage to the professional practice guidelines, and the association of adverse reactions and clinical outcomes with the drug used.  She has published more than sixty research papers in the fields of pharmaceutical sciences, drug safety, and pharmaceutical regulation in internationally recognized medical journals.

 

Speech title & Synopsis

The Next Brave Step: Innovation in Immuno-oncology and the Opportunity for Change for Patients